Publicaciones en colaboración con investigadoras/es de Queen Mary University of London (22)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

2021

  1. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders

    Nature Genetics, Vol. 53, Núm. 11, pp. 1543-1552

  2. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2020

  1. Identification of recurrent mutations in the microrna‐binding sites of b‐cell lymphoma‐ associated genes in follicular lymphoma

    International Journal of Molecular Sciences, Vol. 21, Núm. 22, pp. 1-12

2019

  1. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

    Antiviral Research, Vol. 170

2015

  1. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  2. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 385, Núm. 9963, pp. 117-171

  3. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 386, Núm. 10010, pp. 2287-2323

  4. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: Quantifying the epidemiological transition

    The Lancet, Vol. 386, Núm. 10009, pp. 2145-2191

  5. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 386, Núm. 9995, pp. 743-800

2014

  1. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

    Infection, Vol. 42, Núm. 4, pp. 757-762

  2. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2013

  1. Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients

    PLoS ONE, Vol. 8, Núm. 5

2012

  1. Common values in assessing health outcomes from disease and injury: Disability weights measurement study for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2129-2143

  2. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2197-2223

  3. Mortality after surgery in Europe: A 7 day cohort study

    The Lancet, Vol. 380, Núm. 9847, pp. 1059-1065

  4. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: The EuroSIDA study

    PLoS ONE, Vol. 7, Núm. 7

  5. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2163-2196

2010

  1. Dialysis and renal transplantation in HIV-infected patients: A European survey

    Journal of Acquired Immune Deficiency Syndromes, Vol. 55, Núm. 5, pp. 582-589